{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-278827","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.790850+00:00","generated_at":"2026-05-16T20:33:42.246823+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS","bullets":["Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.","Underwriters granted 30-day option to purchase up to 1,744,186 additional ADSs.","Offering expected to close November 14, 2025; proceeds to fund product development and general corporate purposes.","Existing cash plus net proceeds expected to fund operating expenses into 2028.","Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-278827","json":"https://secwatch.observer/filing/0001193125-25-278827.json","markdown":"https://secwatch.observer/filing/0001193125-25-278827.md","text":"https://secwatch.observer/filing/0001193125-25-278827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525278827/0001193125-25-278827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525278827/d39112d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:33:42.246823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}